First-line pembrolizumab significantly prolonged OS versus chemotherapy in metastatic NSCLC with PD-L1 tumor proportion score (TPS) ≥ 50%, with a 5-year OS rate of 31.9% versus 16.3% and sustained tolerability [93]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.